---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001132"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:47:56.521963+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025

## Summary
- Received Nasdaq letter Dec 31, 2024 for failing to maintain minimum $1.00 bid price for 30 consecutive business days.
- Has 180 calendar days until June 30, 2025 to regain compliance by closing bid price >= $1.00 for 10 consecutive business days.
- If not compliant by June 30, may be eligible for additional 180-day period if meeting other listing standards and intending to cure via reverse stock split.
- Listing continues under symbol SHPH; company considering available options to regain compliance.
- CEO to participate in Lytham Partners fireside chat on Jan 13, 2025; plans to discuss Ropidoxuridine Phase 2 trial and Shuttle Diagnostics.

## SEC filing metadata
- accession: 0001493152-25-001132
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225001132/0001493152-25-001132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225001132/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001132
- JSON: https://secwatch.observer/filing/0001493152-25-001132.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001132.txt

## Source-grounded claims
- claim_id: 3d1ce2f55ba973a3ae61a93ad5d7afe7854d8cf1
  claim: Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: December 30, 2024 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315225001132/0001493152-25-001132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.